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Abstract Careful selection of dominant T cell epitope pep-
tides of major allergens that display degeneracy for binding to
a wide array of MHC class II molecules allows induction of
clinical and immunological tolerance to allergen in a refined
treatment strategy. From the original concept of peptide-
induced T cell anergy arising from in vitro studies, proof-of-
concept murine models and flourishing human trials followed.
Current randomized, double-blind, placebo-controlled clinical
trials of mixtures of T cell-reactive short allergen peptides or
long contiguous overlapping peptides are encouraging with
intradermal administration into non-inflamed skin a preferred
delivery. Definitive immunological mechanisms are yet to be
resolved but specific anergy, Th2 cell deletion, immune devi-
ation, and Treg induction seem implicated. Significant effica-
cy, particularly with short treatment courses, in a range of
aeroallergen therapies (cat, house dust mite, grass pollen) with
inconsequential non-systemic adverse events likely heralds a
new class of therapeutic for allergy, Synthetic Peptide
Immuno-Regulatory Epitopes (SPIRE).
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Introduction
In 1911, Noon pioneered allergen immunotherapy (AIT) for
treatment of grass pollen allergy [1]. The administration of
allergen extracts using various regimens and routes is now
established therapeutic practice in the management of allergic
diseases, and currently the only therapy proven to modify the
natural course of an allergic disease. However, treatment with
whole allergen extracts is contraindicated in patients with un-
stable asthma and food allergies due to the risk of severe IgE-
mediated adverse events including anaphylaxis or even death
[2–4]. These risks, together with the typically prolonged and
frequent dosing regimens, command poor adherence in real
life situations [5] and less than desirable availability of specif-
ic allergy treatments for the burgeoning allergy epidemic [6].
The pivotal role of the CD4+ T cell in driving immune
responsiveness to allergen, together with distinct differences
between T cell and B cell epitopes, facilitates development of
refined therapeutics for redirecting the cellular immune re-
sponse towards peripheral tolerance [7, 8••]. Allergen T cell
epitopes are typically short, without conformational structure.
They fail to cross-link cell-bound IgE or activate inflammato-
ry mast cells and basophils. In contrast, allergen B cell epi-
topes are usually conformational although linear epitopes are
described. On native allergen molecules, B cell epitopes can
bind and cross-link specific IgE on effector cells to trigger
degranulation with inflammatory mediator release and synthe-
sis eliciting the well-recognized features of allergy. Carefully
selected dominant T cell epitope peptides of major clinically
relevant allergens that display degeneracy for binding to a
wide array of MHC class II molecules can safely induce
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clinical and immunological tolerance in a breakthrough new
class of allergy treatment, recently termed Synthetic Peptide
Immuno-Regulatory Epitopes (SPIRE) [8••, 9]. Evolution
from the idea of allergen T cell epitope-based peptide anergy
[10], through proof-of-concept murine experimental models
[11–13], progressed to human clinical translation [14, 15]. In
recent years, there have been randomized, double-blind,
placebo-controlled clinical trials of two types of T cell
epitope-based therapeutics for allergy: short T cell epitope
peptide mixtures and longer Contiguous Overlapping Pep-
tides (COPs) [9, 16•]. Significant efficacy has been achieved
in cat, house dust mite (HDM), and pollen allergy with short
treatment courses and inconsequential non-systemic adverse
events [17, 18••, 19]. Underlying immunological mechanisms
are yet to be clarified but likely include similar changes in
allergen-specific Tcell responses to those seen in conventional
AIT [8••, 20••]. Whether induction of blocking IgG4 antibod-
ies is required for efficacy of peptide immunotherapy is not so
clear and may only be seen using longer peptides such as
COPs or on re-exposure to native allergen [16•]. Promisingly,
T cell epitope peptide therapies suggest efficacy with en-
hanced safety, allowing wider uptake across a range of allergic
conditions.
The focus of this review is the rationale, design and utili-
zation of T cell epitope-based peptides for specific treatment
of al lergic diseases. Selected pept ides comprise
immunodominant Tcell epitopes but not IgE-binding epitopes
and have minimal stimulatory potential for inflammatory
cells. Their presentation is in a form that induces long-
lasting allergen-specific T cell non-responsiveness after only
a short course of treatment. Recent highly encouraging clini-
cal trials of this new class of allergy therapy and associated
data on immunological mechanisms are discussed.
The Rationale for T Cell Epitope Peptide Therapy
for Allergic Diseases
T cell epitope peptide therapy harnesses the established im-
munological dogma that dominant T cell epitope peptides can
induce anergy of specific Tcells if delivered in a way that fails
to activate the T cell [21]. Induction of specific anergy utilizes
the functional cytokine plasticity of Th cells to downregulate
aberrant effector Tcell responses while providing the cytokine
milieu and impetus for naive T cells to establish protective
responses [22, 23]. Additionally, the pattern of conserved T
cell epitope repertoires observed in HDM-allergic individuals
during longitudinal screening over 2 years supports this ap-
proach in contrast to the more changeable T cell specificities
observed in longitudinal screening in autoimmune disease
[24, 25]. Human T cell receptor repertoire analysis identified
TCR-Vα and TCR-Vβ gene segment usage bias, together
with in vivo clonal dominance by long-lived HDM-specific
T cell clones [26]. Similar in vivo longevity of venom-specific
T cell clones was reported [27]. Most importantly, functional
plasticity of Tcells derived from the same clonal origin allows
switching from dominant IL-4 to IL-10 or IFN-γ production
during anergy induction in vitro or AIT [27–29]. Another
study demonstrated preferential loss (deletion) of pathogenic
Th2 T cells specific for dominant allergen epitopes following
successful pollen immunotherapy using fluorochrome-
conjugated HLA class II-peptide tetramers to quantify these
Tcells directly ex vivo [30••]. These features support the view
that induction of specific anergy or selective elimination of
dominant clonal populations of pathogenic allergen-specific
T cells would be of therapeutic benefit in the treatment of
allergic diseases.
Design of T Cell Epitope Peptide Therapies
for Allergic Diseases
T Cell Epitope Mapping of Major Allergens
T cell epitope peptide therapies rely on the identification of
immunodominant CD4+ Tcell epitopes within major, clinical-
ly relevant allergens. Molecular cloning, characterization and
sequencing of allergens allow the synthesis of nested sets of
overlapping peptides covering the full allergen sequence.
Mapping of T cell epitopes can then be performed using pe-
ripheral blood mononuclear cells (PBMC) from individuals
with the specific allergy of interest, either directly ex vivo,
or after enrichment for allergen-specificity as T cell lines
(oligoclonal populations) or T cell clones (monoclonal popu-
lations). The most critical peptides are identified by a range of
immunological assays utilising sophisticated and/or high-
throughput methodologies. These include flow cytometry
using dyes such as carboxyfluorescein diacetate succinimidyl
ester (CFSE) to detect proliferating cells by decreased inten-
sity of staining [31, 32], cytokine capture [33], and
fluorochrome-conjugated HLA class II-peptide tetramers
[27, 34]. CFSE-based approaches are sensitive for detection
of peptide-responsive T cells, particularly when combined
with other activation markers such as CD25 (our unpublished
observation), but bystander proliferation may reduce specific-
ity [35•]. ELISPOT-based approaches can be used for high-
throughput screening of PBMC for T cell epitope peptide rec-
ognition [33, 36, 37]. Identified T cell epitopes are then vali-
dated by screening large patient population cohorts and using
rigorous assay design and appropriate statistical methods (e.g.,
[34]).
HLA-peptide tetrameric complexes are sensitive and spe-
cific analytes for identification and characterization of
allergen-specific T cells directly ex vivo, but tetramer synthe-
sis is expensive and many HLA class II molecules are not
easily isolated for use in tetramers, limiting the HLA-
14 Page 2 of 9 Curr Allergy Asthma Rep (2016) 16: 14
coverage obtainable [27, 34]. Unlike CFSE-approaches,
tetramer-based methodologies may lack sensitivity despite
high specificity [35•]. Alternatively, in silico algorithms con-
sider thousands of known epitope sequences to predict CD4+
T cell epitopes by detecting theoretical HLA class II binding
motifs within protein sequences [38]. While algorithms
provide preliminary guidance cost-effectively, compre-
hensiveness is limited and HLA-binding motif predic-
tions require validation in functional peripheral blood
T cell assays [35•, 39].
Most frequently, for identification of all potential T cell
epitopes, allergen-specific T cell lines and clones from large
patient cohorts are screened for reactivity against overlapping
synthetic peptides spanning the entire sequence of the allergen
molecule, each usually 15 to 20 amino acids long with over-
laps from 5 amino acids upwards. Core epitopes within T cell-
reactive peptides are mapped subsequently using peptide sets
truncated from the N- and C-termini, typically revealing eight
or nine residue core epitopes for CD4+ T cells. Optimal T cell
stimulation often requires longer sequences including flanking
residues to stabilize the HLA-peptide-TCR complex and im-
prove expression of peptide on the antigen presenting cell
surface [40–42]. Consistent with naturally processed peptides
eluted from HLA class II molecules, candidate peptides for
inclusion in short allergen peptide therapy range from 12–20
residues [43, 44].
A catalogue of allergen T cell-reactive sites mapped to date
is available from The Immune Epitope Database (IEDB)
[45–47]. Meta-analysis identified 1406 allergen-derived
CD4+ T cell epitopes derived from human T cell reactivity
[48]. Despite large numbers, it is estimated that this represents
<17 % of all allergens in the International Union of Immuno-
logical Societies (IUIS) allergen database [49]. T cell epitopes
are found scattered throughout an allergen sequence, but con-
sideration of collective properties of the epitopes allows rank-
ing according to dominance to optimize peptide candidates for
therapy [38]. Such properties include donor and T cell
line/clone responder frequency, patterns of reactivity, repro-
ducibility of T cell response and, importantly, ability to induce
a response in patient PBMC in large patient cohorts. Identifi-
cation of the most immunodominant T cell epitopes is impor-
tant, recognizing another important immunological dogma
that the stronger the immunogen the stronger the tolerogen
[50]. With neighboring or overlapping epitopes, a single pep-
tide containing the two epitopes may allow targeting of both T
cell specificities while minimising final peptide length and
number. However, validation of T cell recognition of both
epitopes in the consolidated peptide is required, and in our
experience, not always obtained, requiring retention of indi-
vidual T cell epitope peptides. Cross-reactive T cell epitopes
are present in some closely related allergens, e.g. group 1 grass
pollen allergens [51–53], which aids broader population cov-
erage in different regions.
For optimal production, modification of some peptides
may aid solubility and stability, for example, modification of
terminal residues and replacement of cysteine residues with
inert alanine or non-reactive serine to prevent aggregation
(e.g. [32]). Testing T cell reactivity of any modified peptide
is necessary to confirm retention of Tcell stimulatory capacity.
As a safety index, all candidate T cell epitope peptides need
testing singly and in combination to exclude potential engage-
ment and cross-linking of inflammatory cell-bound IgE. The
flow cytometric basophil activation test or the histamine re-
lease test are increasingly utilized as convenient and validated
read-outs of clinically relevant, functional IgE reactivity
[54–57].
MHC Class II Restriction Specificity
The ability of T cell epitope peptide candidates for therapy to
show widespread degeneracy of binding to a range of MHC
class II molecules is important when targeting genetically di-
verse patient populations. Human CD4+ T cells recognize al-
lergen epitopes in the context of particular HLA class II mol-
ecules encoded by one of three highly polymorphic loci,
HLA-DR, HLA-DP, or HLA-DQ. HLA-binding Tcell epitope
prediction algorithms are popular but with variable correlation
when compared with direct functional assays. Early algo-
rithms were limited to HLA-DR binding motifs, but now ex-
tend to HLA-DQ and -DP predictions [38]. Experimental val-
idation of predicted epitopes utilizes isolated HLA molecules
and/or transfected L cells or EBV-transformed B cell lines
homozygous for defined HLA alleles [8••, 58]. HLA-peptide
binding assays help inform clinical relevance in addition to
levels of avidity and/or affinity [40, 58, 59].
However, to identify the full repertoire of functional HLA-
peptide complexes, functional read-outs of T cell proliferation
or cytokine production with the particular HLA-peptide com-
plex are needed. Preliminary screening of HLA-restriction
specificity of T cell epitope recognition is achieved by using
blocking monoclonal antibodies specific for HLA-DR, HLA-
DP or HLA-DQ [8••, 32]. HLA-genotyping of the antigen
presenting cells can then inform restriction to specific HLA-
subtype(s). Tetramers provide a more sophisticated method
for screening in samples such as blood analyzed directly
ex vivo [34] but, problematically, screens utilizing tetramers
or homozygous cell lines need HLA-matched CD4+ T cells/
patients [60] and as discussed above, the available range of
testable HLA tetramers is limited.
It is helpful that allergen T cell epitopes frequently display
extensive HLA-binding degeneracy while allergen-specific
CD4+ Tcells may recognize a particular epitope in the context
of multiple HLA class II molecules [30••, 32, 33, 37, 38,
61–63]. Nominal antigens are most commonly presented on
HLA-DR molecules, but allergen T cell epitopes are also pre-
sented on HLA-DQ and HLA-DP molecules (reviewed in
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[8••]). HLA-DQ and HLA-DP subtypes are often conserved
more broadly across populations than HLA-DR molecules,
for example HLA-DP*0401 and/or 0402 alleles are expressed
in ~50 % of the Caucasian population [64].
Learning from Experimental Models of Allergen T
Cell Epitope Peptide Immune Modulation
In the early 1990s, O’Hehir and colleagues demonstrated that
overnight incubation of cloned human T cells reactive with
Der p 1 (major HDM allergen) with a supraoptimal concen-
tration of their dominant T cell epitope peptide could induce
specific non-responsiveness to that peptide [65]. The induc-
tion phase of anergy in this allergy model was associated with
t rans ien t re lease of Th2 cytokines (notably the
bronchoconstrictor IL-4) as though by hyper-excitation
followed by anergy [8••, 28, 29]. Established anergy was ac-
companied by decreased IL-4 and IL-5 synthesis but main-
tained IFN-γ and IL-10 production [28, 65]. Defective TCR
signalling was demonstrated by abrogated activity of p56lck
and ZAP-70 tyrosine kinases in a bee venom allergen (PLA2)-
specific CD4+ T cell model [66].
Proof-of-concept for clinical translation was established
initially using murine models of HDM and cat allergy [11,
12]. Importantly, these studies showed that delivering
supraoptimal concentrations of a single dominant T cell epi-
tope peptide in vivo not only induced specific non-
responsiveness to subsequent challenge with that peptide,
but also to whole allergen extract, known as linked suppres-
sion. Such linked epitope suppression confirmed in vivo ap-
plicability of allergen T cell epitope peptides to treat allergic
disease. Subsequently, the robustness of this approach was
validated in other allergen models (see review [8••]). Using
HLA-DR1 tetramer technology in a murine cat allergy model,
Campbell et al. identified Fel d 1 T cell epitope peptide-
induced linked epitope suppression associated with IL-10+ T
cells [67]. In a murine ovalbumin TCR transgenic model,
Mackenzie et al. adoptively transferred Th2-polarized cells
to show preferential effects of peptide immunotherapy on cy-
tokine secretion by CD62Llo cells (effector and effector mem-
ory T cells) rather than CD62LhiTh2 cells (central memory T
cells) in downregulation of airway inflammation [68].
Clinical Translation of T Cell Epitope Peptide
Therapy for Allergy
Learning from Early Trials of Allergen Peptides in Bee
Venom and Cat Allergy
Pioneering in vivo studies in bee venom allergy confirmed
that immunodominant T cell epitope peptides administered
by subcutaneous injection induced clinical tolerance without
severe adverse reactions [15]. However, these studies did not
progress due to the unpredictable natural history of reactions
to bee venom.
Pilot studies in cat allergy showed variable efficacy, but
large protein determinants from Fel d 1 were trialled in these
early studies rather than minimal epitopes [14, 69]. A double-
blind placebo-controlled trial in 95 cat-allergic subjects com-
prising 4 subcutaneous doses of a Fel d 1 peptide mix
(Allervax®CAT) or placebo showed clinical benefit of the
peptide treatment after 6 weeks [14]. However, a range of
adverse events was noted (nasal congestion, flushing, pruritus,
chest tightness from minutes to hours after peptide delivery).
Late asthmatic responses were triggered in some trial subjects
with or without known asthma, and these were shown to be
due to cytokines from peptide-stimulated T cells [70, 71]. It is
tempting to speculate that the observed bronchospasm was
due to the initial T cell activation and cytokine flare
(particularly bronchoconstrictor IL-4) reported early in the
induction phase of allergen peptide-induced anergy in vitro
[28, 29]. Repeated delivery and dosage adjustment attenuated
the late reaction without losing efficacy. Nevertheless, these
early studies with higher concentrations of longer peptides
administered subcutaneously were disappointing in failing to
achieve sustained clinical efficacy [71, 72].
Synthetic Peptide Immuno-Regulatory Epitope Therapy:
a New Class of Anti-allergy Therapeutic
Short Allergen T Cell Epitope Peptides
Innovative research lead by Larché and Kay in the late 1990s
and early 2000s evolved into second generation Tcell epitope-
based allergen peptides [70, 73]. Typically, these allergy ther-
apeutic candidates are now mixtures of short peptides admin-
istered intradermally (≤12 nmol; ~75 μg vs 750 μg) into non-
inflamed skin [9, 18••, 56, 73–76]. While earlier studies uti-
lized the subcutaneous route for peptide administration, a sub-
sequent study directly comparing intradermal with subcutane-
ous cat peptide delivery, showed that the intradermal route had
superior immunological activity as well as tolerability [56].
The first of the new-generation peptide treatment to be trialled,
Cat-PAD (Circassia Ltd; Oxford, UK), comprised of 7 T cell
epitope-based peptides (13–17 amino acids) from Fel d 1as a
lyophilisate reconstituted in water for intradermal administra-
tion. Recent trials have used a painless, needle-free transder-
mal delivery for four to eight treatments at 2–4-week intervals
with recording of Total Rhino-conjunctivitis Symptom Score
and challenge testing in an Environmental Exposure Chamber
[18••, 77]. By using short T cell epitope-based peptides, IgE
cross-linking and inflammatory cell activation was avoided,
and careful dose adjustments prevented the late asthmatic re-
sponses seen earlier with longer peptides. A phase IIb clinical
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field trial indicated sustained clinical efficacy out to 2 years
after the initial course of Cat-PAD [78••]. As expected in a
clinical trial of an allergy therapy [79, 80], substantial placebo
effects were seen initially but were not sustained longer term.
Trials of short peptide therapies exploring optimal regimens in
HDM [17, 81], grass pollen [82], and ragweed pollen allergy
[83] are ongoing with encouraging early findings.
Contiguous Overlapping Peptides
In parallel, a second approach utilising longer T cell epitope-
based allergen peptides, termed contiguous overlapping pep-
tides (COPs), is under active investigation and early phase
clinical trials [16•, 84, 85]. In this strategy, all possible T cell
epitopes of the target allergen (birch pollen being the proto-
type) are included in a small set of long synthetic peptides but
conformational IgE epitopes are disrupted. Phase 1/IIa clinical
trials in bee venom and birch pollen allergy failed to invoke
early IgE-mediated reactions and demonstrated increased spe-
cific IgG4 antibodies as observed with conventional AIT. A
regimen tested in subjects with birch pollen allergy, compris-
ing five injections in 2 months, resulted in improved nasal
provocation scores. As seen in the early cat peptide trials,
higher concentrations of COPs also invoked late asthmatic
responses that were absent with lower peptide concentrations
[16•]. It is again tempting to suggest that a surge of IL-4
release during the induction phase of anergy could explain
the bronchoconstriction as a transient effect. While encourag-
ing, further trial results for COPs are needed for convincing
proof of efficacy.
Analysis of Mechanisms of Action
As clinical translation of T cell epitope peptide therapy for
allergy progresses, the underlying immunological mecha-
nisms must be fully elucidated [20••, 86]. With increasing
data, distinct differences are evident from conventional AIT
[87, 88]. As seen in effective AIT with whole allergen, de-
creased T cell proliferative and cytokine response to allergen
appear to follow allergen peptide immunotherapy (e.g., [72,
76]), but the precise mechanism is elusive to date. Some hall-
marks of anergy are evident from the pilot bee venom study, in
which decreased PLA2-specific T cell proliferation and de-
creased IL-2, IL-4, IL-5, IL-13, and IFN-γ production could
be reversed by IL-2 and IL-15 [15]. However, in these early
experiments, the polyclonal cultures and limited phenotyping
precluded delineation of re-activated anergized T cells and
activated naive T cells or even Treg. A role for deletion of
allergen-specific T cells is also feasible from the murine
models. In a recent study of conventional subcutaneous AIT
for grass pollen allergy, HLA class II tetramers were used to
quantify allergen-specific clonal T cell populations ex vivo
[30••]. Findings were consistent with preferential loss of clon-
al Th2-type T cells specific for dominant epitopes of major
grass pollen allergens over T cells specific for less-dominant
epitopes with a Th-1 or Tr1-phenotype. However, tetrameric
approaches rely on TCR detection on the cell surface which
may be confounded by down-regulation of TCR expression
on anergic T cells. In this study, the pathogenic Th2 cells also
lacked CD27 expression as an additional marker suggesting
selective loss of these cells.
Increased synthesis of IL-10 and induction of Treg are con-
sistently reported as mechanisms of effective conventional
AIT. Comparably, similar findings were reported in the early
bee venom and cat allergen peptide studies [72, 89]. Specifi-
cally, the studies of cat allergen peptide treatment demonstrat-
ed a requirement for IL-10 in order to induce suppression of
allergen-specific responses and invoke linked epitope sup-
pression [67], and also to see an allergen-specific CD4+ Treg
population [90]. Skin allergen challenge biopsies revealed en-
hanced CD4+IFN-γ+ and CD25+ cells following peptide treat-
ment consistent with immune deviation and Tregs [91]. How-
ever, the overlap between surface markers on effector cells
and Tregs, particularly when activated, makes interpretation
of clinical biopsies difficult [92].
Peptide lengths selected for T cell epitope-based therapy
may determine whether specific IgG4 blocking antibody is
generated. Peptides based on individual minimal T cell epi-
tope sequences are short and screened for lack of IgE binding
and inflammatory cell activating potential, so would seem less
likely to be immunogenic. Nevertheless, boosting by exposure
to whole allergen in a modified cytokine milieu might con-
ceivably drive IgA or IgG4 antibody production. The initial
pilot bee venom study detected no antibody changes but, fol-
lowing subcutaneous rechallenge with whole allergen, an in-
crease in specific IgG4 could be detected [15]. In a study by
Tarzi et al., only a negligible and transient elevation in specific
IgG4 was seen [89]. In contrast, repeated administration of
COPs for birch pollen allergy resulted in a marked increase
in Bet v 1-specific IgG4 levels over baseline and compared
with placebo [16•]. As the data from current and future clinical
trials accumulate, there will be greater appreciation of IgG4
changes as mechanistic or an epiphenomenon. Blocking anti-
bodies are demonstrably important in conventional AIT but
seem less relevant for sustained unresponsiveness [20••, 93].
Conclusions
A new class of specific T cell epitope peptide therapy for
allergic diseases, perhaps to be known as SPIRE, is growing
in momentum with encouraging data in clinical trials across a
range of allergens. Immunodominant T cell epitope-based al-
lergen peptides seem able to induce sustained clinical toler-
ance although the underlying immunological mechanisms are
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yet to be clarified. Core epitope mapping to inform peptide
selection identifies the critical amino acid sequences that can
invoke desired clinical tolerance without undesirable cell-
bound IgE cross-linking and inflammatory sequelae. Promis-
cuity of binding of these dominant allergen peptides to a wide
range of HLA class II molecules offers widespread clinical
utility without need for individual patient endotyping. In par-
ticular, emerging evidence of sustained efficacy in the pres-
ence of ongoing exposure to ensure retained memory after
relatively short treatment courses without adverse events gives
hope that allergology is poised for a therapeutic revolution.
The observed pattern of efficacy suggests an important role for
anergy as a key mechanism for this class of therapy. Expan-
sion of this treatment approach to encompass specific thera-
pies for food allergies, particularly peanut allergy, is advanced
and early phase trials are awaited with interest. Additionally,
research into possible applicability for mould allergy and
cockroach allergy seems worthy of concentrated effort. After
more than 100 years since specific immunotherapy was intro-
duced as a treatment to modify the natural course of allergic
disease, it is gratifying that harnessing fundamental immuno-
logical principles may allow more widespread modulation of
the aberrant immune response to allergens that causes such a
major socio-economic health burden globally.
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